Perflubron as an oral contrast agent for MR imaging: results of a phase III clinical trial.

Mattrey, Robert F.; Trambert, Michael; Brown, Jeffrey J.; Young, Stuart W.; Bruneton, J.; Wesbey, George E.; Balsara, Z N

doi:10.1148/radiology.191.3.8184076

Cited by 48 publications

(24 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Traditional barium meals provide contrast in CT, and virtual colonoscopy is competing with traditional fiber optic probes [388]. MR procedures have lagged behind CT, but several potential contrast agents have been presented, ranging from paramagnetic zeolite formulations [389] and ferric ammonium citrate [390] to PFC emulsions [391,392] and recently images were shown in mice based on perfluorononane [69].…”

Section: Passive Reporter Moleculesmentioning

confidence: 99%

VatuximabTM: Optimizing Therapeutic Strategies for Prostate Cancer Based on Dynamic MR Tumor Oximetry

Mason¹

2007

View full text Add to dashboard Cite

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.

show abstract

Section: Passive Reporter Moleculesmentioning

confidence: 99%

VatuximabTM: Optimizing Therapeutic Strategies for Prostate Cancer Based on Dynamic MR Tumor Oximetry

Mason¹

2007

View full text Add to dashboard Cite

show abstract

“…For MRI, the multi-resonance spectrum requires extensive editing. PFOB has been tested in clinical trials [276,277] and recently images were shown in mice based on 5. METABOLISM AND DRUG UPTAKE perfluorononane [278].…”

Section: Hypoxia Hypoxic Fraction and In Vivo Nitroreductase Activitimentioning

confidence: 99%

Breast Cancer Gene Therapy: Development of Novel Non-Invasive Magnetic Resonance Assay to Optimize Efficacy

Mason¹

2005

View full text Add to dashboard Cite

Public reporting burden for this collection of information Is estimated to average 1 hour per response, Including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, ABSTRACT (Maximum 200 Words)Gene therapy holds great promise for treatment of breast cancer. In particular, clinical trials are underway to apply therapeutic genes related to pro-drug activation or to modulate the activity of oncogenes by blocking promoter sites. However, there are major problems in terms of assessing the delivery to target tissue, assessing the uniformity (versus heterogeneity) of biodistribution and determining whether the genes are expressed. We propose to design, evaluate and apply a novel approach to gene activity detection-specifically, using fluorinated substrates of P-galactosidase to reveal gene activity. Our prototype molecule PFONPG (para-fluoro-ortho-nitro-phenyl P3-D-galactopyranoside) is a direct analog of the traditional "yellow' biochemical indicator ONPG (ortho-nitro-phenyl 3-D-galactopyranoside). This shows useful MR characteristics, sensitivity to enzyme activity and ability to enter cells. We will synthesize analogs of this prototype to optimize MR and biological characteristics and explore the feasibility of tailoring the reporter to specific applications, e.g., exploiting P-gal activity to deliver specific physiological reporter molecules such as pH and potentially specific cytotoxic agents. The agents will be rigorously tested in solution, applied to cultured breast cancer cells and ultimately used to examine P-gal activity in vivo in transfected breast tumors in mice and rats. SUBJECT TERMS NUMBER OF PAGESGene therapy, fluorine NMR, P-galactosidase, pH 127 IntroductionGene therapy holds great promise for treatment of breast cancer (1, 2). In particular, clinical trials are underway to apply therapeutic genes related to pro-drug activation or modulation of the activity of oncogenes by blocking promoter sites. However, there are major problems in terms of assessing the delivery to target tissue, assessing the uniformity (versus heterogeneity) of biodistribution and determining whether the genes are expressed. We propose to design, evaluate and apply a novel approach to gene activity detection-specifically, using fluorinated substrates of P3-galactosidase to reveal gene activity. Our prototype molecule PFONPG (para-fluoro-ortho-nitro-phenyl [3-D-galactopyranoside) is a direct analog of the traditional "yellow' biochemical indicator ONPG (ortho-nitro-phenyl 13-D-galactopyranoside).This shows useful MR characteristics, sensitivity to enzyme activity ...

show abstract

“…Since the magnetic properties of 19 Ffluorocarbons correlate with organ oxygen content, perfluorocarbons tagged with 19 F can be used as diagnostic tools to assess tissue oxygenation by magnetic resonance imaging [46,47]. In addition, some perfluorocarbons can also be used as contrast agents in sonography, computed tomography, and conventional radiology [48,49]. In the area of hemoglobinbased oxygen carriers further interesting developments will result from advances in biotechnology.…”

Section: Experimental Use Of Artificial Oxygen Carriersmentioning

confidence: 99%

Biomedical Applications of Artificial Oxygen Carriers

Waschke¹,

Lenz²

1999

Transfus Med Hemother

View full text Add to dashboard Cite

At present, the rapid progress in science and technology around artificial oxygen carriers has advanced to a critical stage.Therefore, it can be assumed that these substances will be clinically available as substitutes for red blood cells within the next years. It can be expected that the major impact of hemoglobin- and perfluorocarbon-based oxygen carriers will be on the use as intermittent blood substitutes during or anticipating acute blood loss from surgery or trauma. However, further applications for artificial oxygen carriers are emerging which cannot fullfilled by red blood cells. Clinical studies are testing now the therapeutic abilities of artificial oxygen carriers in renal anemia, transplantation medicine, cancer therapy, sickle cell disease, treatment of septic shock, treatment of stroke, reduction of air embolism during cardiopulmonary bypass, and as an adjunct to respiratory therapy (‘liquid ventilation’) . In addition, use of artificial oxygen carriers in animal experiments aims at the improvement of oxygen supply in the microcirculation of organs suffering from ischemia. For the long term, biological engineering may increase desired pharmacologic properties of artificial oxygen carriers and widen their spectrum of indications.

show abstract

Perflubron as an oral contrast agent for MR imaging: results of a phase III clinical trial.

Abstract: Perflubron is safe, and its efficacy was unaffected by pulse sequences, magnetic field strength, or time delay.

Cited by 48 publications

References 0 publications

VatuximabTM: Optimizing Therapeutic Strategies for Prostate Cancer Based on Dynamic MR Tumor Oximetry

VatuximabTM: Optimizing Therapeutic Strategies for Prostate Cancer Based on Dynamic MR Tumor Oximetry

Breast Cancer Gene Therapy: Development of Novel Non-Invasive Magnetic Resonance Assay to Optimize Efficacy

Biomedical Applications of Artificial Oxygen Carriers

Contact Info

Product

Resources

About